Figure 4.
EFS and OS of aggressive large B-cell NHL treated with CD19-specific CAR T-cell therapy. (A) EFS (1-year EFS, 40%). (B) OS (1-year OS, 69%).

EFS and OS of aggressive large B-cell NHL treated with CD19-specific CAR T-cell therapy. (A) EFS (1-year EFS, 40%). (B) OS (1-year OS, 69%).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal